WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced data from AbbVie’s SURVEYOR studies of its investigational treatment regimen, consisting of ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, that show high rates of sustained virologic response at 12 weeks post-treatment (SVR12) in non-cirrhotic patients with chronic hepatitis C virus (HCV) infection. After 12 weeks of treatment, SVR12 rates achieved were 97-100 percent in genotype 1 (GT1) patients, 96-100 percent in genotype 2 (GT2), and 83-94 percent in genotype 3 (GT3).1,2,3 These data will be presented at The Liver Meeting®, which is the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
Separately, in a late-breaking presentation of the SURVEYOR-1 trial, additional data will show non-cirrhotic GT1 chronic HCV patients who received a shorter duration of treatment for 8 weeks with ABT-493 and ABT-530 achieved a SVR12 rate of 97 percent.4
For full article, please click here.
Help employers find you! Check out all the jobs and post your resume.
